Home  |  Contact

Cellosaurus ME-180 (CVCL_1401)

[Text version]

Cell line name ME-180
Synonyms Me-180; ME 180; ME180
Accession CVCL_1401
Resource Identification Initiative To cite this cell line use: ME-180 (RRID:CVCL_1401)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
Characteristics: Contains a complete HPV68 genome.
Doubling time: 1.5 days (PubMed=29156801).
Microsatellite instability: Stable (MSS) (Sanger).
Transformant: NCBI_TaxID; 45240; Human papillomavirus type 68 (HPV68).
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations Heterozygous for PIK3CA p.Glu545Lys (c.1633G>A) (CCLE; Cosmic-CLP).
Has no TP53 mutation (PubMed=9887230).
Genome ancestry Source: PubMed=30894373

Origin% genome
African1.51
Native American0.16
East Asian, North1.49
East Asian, South0
South Asian0
European, North64.3
European, South32.53
Disease Human papillomavirus-related cervical squamous cell carcinoma (NCIt: C27676)
Derived from metastatic site: Omentum.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_KS60 (CellSensor AP1-bla ME-180)CVCL_KS68 (CellSensor c-fos-bla ME-180)CVCL_KS52 (CellSensor GAS-bla ME-180)
CVCL_KS07 (CellSensor HRE-bla ME-180)CVCL_KB44 (CellSensor NFkB-bla ME-180)CVCL_KS28 (CellSensor SIE-bla ME-180)
CVCL_0473 (OV-2008)CVCL_6950 (SF767)CVCL_A342 (TSGH-8301)
Sex of cell Female
Age at sampling 66Y
Category Cancer cell line
STR profile Source(s): ATCC; CCRID; Cosmic-CLP; JCRB; KCLB; PubMed=22710073; PubMed=25877200; PubMed=29156801; RCB; TKG

Markers:
AmelogeninX
CSF1PO11
D2S133818
D3S135816
D5S81812
D7S8209,10
D8S117914
D13S31711,13 (ATCC; CCRID; Cosmic-CLP; JCRB; KCLB; PubMed=25877200; PubMed=29156801; RCB; TKG)
11,12 (PubMed=22710073)
D16S53912,13
D18S5112
D19S43313,15.2
D21S1130,31
FGA23
Penta D9,14
Penta E12,14
TH018,9.3 (ATCC; CCRID; Cosmic-CLP; JCRB; KCLB; PubMed=22710073; PubMed=25877200; PubMed=29156801; TKG)
8 (RCB)
TPOX8,10
vWA15,17 (ATCC; CCRID; Cosmic-CLP; KCLB; PubMed=22710073; PubMed=25877200; PubMed=29156801; RCB; TKG)
15,16,17 (JCRB)

Run an STR similarity search on this cell line
Web pages http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-612.html
http://www.cellresource.cn/fdetail.aspx?id=1688
Publications

PubMed=4317734; DOI=10.1093/jnci/45.1.107
Sykes J.A., Whitescarver J., Jernstrom P., Nolan J.F., Byatt P.
Some properties of a new epithelial cell line of human origin.
J. Natl. Cancer Inst. 45:107-122(1970)

DOI=10.1007/978-1-4757-1647-4_13
Biedler J.L.
Chromosome abnormalities in human tumor cells in culture.
(In) Human tumor cells in vitro; Fogh J. (eds.); pp.359-394; Springer; New York (1975)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=7017212; DOI=10.1093/jnci/66.6.1003
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
J. Natl. Cancer Inst. 66:1003-1012(1981)

PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

PubMed=6220172
Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=6500159; DOI=10.1159/000163283
Gershwin M.E., Lentz D., Owens R.B.
Relationship between karyotype of tissue culture lines and tumorigenicity in nude mice.
Exp. Cell Biol. 52:361-370(1984)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=2990217
Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., Howley P.M.
Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines.
Am. J. Pathol. 119:361-366(1985)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3371749; DOI=10.1016/0090-8258(88)90029-7
Grenman S.E., Shapira A., Carey T.E.
In vitro response of cervical cancer cell lines CaSki, HeLa, and ME-180 to the antiestrogen tamoxifen.
Gynecol. Oncol. 30:228-238(1988)

PubMed=8380785; DOI=10.1006/gyno.1993.1016
Iwasaka T., Oh-uchida M., Matsuo N., Yokoyama M., Fukuda K., Hara K., Fukuyama K., Hori K., Sugimori H.
Correlation between HPV positivity and state of the p53 gene in cervical carcinoma cell lines.
Gynecol. Oncol. 48:104-109(1993)

PubMed=7751322; DOI=10.1007/BF01366967
Rantanen V., Grenman S.E., Kulmala J., Grenman R.
The intrinsic radiosensitivity and sublethal damage repair capacity of five cervical carcinoma cell lines tested with the 96-well-plate assay.
J. Cancer Res. Clin. Oncol. 121:230-234(1995)

PubMed=8931502; DOI=10.3109/00016349609054706
Iwasaka T., Zheng P.-S., Ouchida M., Yamasaki H., Yokoyama M., Sugimori H.
Cytologic changes in two cervical carcinoma cell lines after transfection of the wild-type p53 gene.
Acta Obstet. Gynecol. Scand. 75:797-803(1996)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=9887230; DOI=10.1006/gyno.1998.5194
Rantanen V., Grenman S., Kurvinen K., Hietanen S., Raitanen M., Syrjanen S.
p53 mutations and presence of HPV DNA do not correlate with radiosensitivity of gynecological cancer cell lines.
Gynecol. Oncol. 71:352-358(1998)

PubMed=15531914; DOI=10.1038/sj.onc.1208235
Baldus S.E., Schwarz E., Lohrey C., Zapatka M., Landsberg S., Hahn S.A., Schmidt D., Dienes H.-P., Schmiegel W.H., Schwarte-Waldhoff I.
Smad4 deficiency in cervical carcinoma cells.
Oncogene 24:810-819(2005)

PubMed=17325662; DOI=10.1038/sj.onc.1210330
Nakaya K., Yamagata H.D., Arita N., Nakashiro K.-I., Nose M., Miki T., Hamakawa H.
Identification of homozygous deletions of tumor suppressor gene FAT in oral cancer using CGH-array.
Oncogene 26:5300-5308(2007)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017
Korch C., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012)

PubMed=24134916; DOI=10.1186/1755-8166-6-44
McCormack A., Fan J.L., Duesberg M., Bloomfield M., Fiala C., Duesberg P.
Individual karyotypes at the origins of cervical carcinomas.
Mol. Cytogenet. 6:44-44(2013)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27561551; DOI=10.1038/ncomms12645
Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.Y., Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.
Nat. Commun. 7:12645-12645(2016)

PubMed=29156801; DOI=10.18632/oncotarget.21174
Kalu N.N., Mazumdar T., Peng S., Shen L., Sambandam V., Rao X., Xi Y., Li L., Qi Y., Gleber-Netto F.O., Patel A., Wang J., Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.
Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines.
Oncotarget 8:86369-86383(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

Cross-references
Cell line collections ATCC; HTB-33
ATCC; CRL-7932 - Discontinued
ICLC; HTL96027
JCRB; JCRB0810
KCLB; 30033
RCB; RCB2106
TKG; TKG 0437
Cell line databases/resources CLDB; cl3429
CCLE; ME180_CERVIX
CCRID; 3131C0001000700177
Cell_Model_Passport; SIDM00627
Cosmic-CLP; 687514
DepMap; ACH-001359
GDSC; 687514
IGRhCellID; ME180%20GEO
LINCS_LDP; LCL-1305
TOKU-E; 2410
Ontologies CLO; CLO_0007657
CLO; CLO_0050924
EFO; EFO_0006646
Biological sample resources BioSample; SAMN03471125
BioSample; SAMN03472007
BioSample; SAMN03472511
BioSample; SAMN03473047
Chemistry resources ChEMBL-Cells; CHEMBL3308114
ChEMBL-Targets; CHEMBL1075499
PharmacoDB; ME180_910_2019
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-3610
GEO; GSM113864
GEO; GSM253300
GEO; GSM595618
GEO; GSM675736
GEO; GSM685436
GEO; GSM827202
GEO; GSM1670090
Other Wikidata; Q54904901
Polymorphism and mutation databases Cosmic; 687514
Cosmic; 760223
Cosmic; 809228
Cosmic; 846185
Cosmic; 877466
Cosmic; 928909
Cosmic; 1071909
Cosmic; 1102582
Cosmic; 1131524
Cosmic; 1175837
Cosmic; 1176609
Cosmic; 1193031
Cosmic; 1995503
Cosmic; 2301541
Cosmic; 2546868
Cosmic; 2660192
IARC_TP53; 21490
Entry history
Entry creation04-Apr-2012
Last entry updated06-Sep-2019
Version number30